FindTrial
Sign In

Cognitive effects of adjuntive Vortioxetine in early Schizophrenia

Status
Not yet recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519778-38-00
Enrollment
37
Registered
2024-12-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

squizophrenia, Schizophrenia spectrum disorders

Brief summary

Primary outcome measures: Cognitive functioning improvement assessed by the change in BACS App scores.

Interventions

DRUGQUETIAPINE
DRUGPIMOZIDE
DRUGVORTIOXETINE
DRUGCHLORPROMAZINE
DRUGRISPERIDONE
DRUGOLANZAPINE
DRUGZIPRASIDONE
DRUGARIPIPRAZOLE
DRUGTHIORIDAZINE
DRUGHALOPERIDOL

Sponsors

Fundacion Para La Gestion De La Investigacion En Salud De Sevilla
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Primary outcome measures: Cognitive functioning improvement assessed by the change in BACS App scores.—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026